Amygdala Neurosciences is developing ANS-6637 a new chemical entity with a novel MOA for treating substance use disorder and behavior based addictions. Based on a mechanism of action in the brain (published in Nature Medicine) that prevents pathophysiologic dopamine surge without changes to basal dopamine, ANS-6637 has the potential to prevent drug seeking behavior, craving and relapse.
